BR0212822A - Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas - Google Patents

Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas

Info

Publication number
BR0212822A
BR0212822A BR0212822-5A BR0212822A BR0212822A BR 0212822 A BR0212822 A BR 0212822A BR 0212822 A BR0212822 A BR 0212822A BR 0212822 A BR0212822 A BR 0212822A
Authority
BR
Brazil
Prior art keywords
crystalline forms
forms
crystalline
compound
hydroxyacetyl
Prior art date
Application number
BR0212822-5A
Other languages
English (en)
Inventor
Kimberley C Allen
Jerry D Clark
Thomas P Fraher
Jason A Hanko
Kimberly L Kolbert
Clay R Little
Michael K Mao
Patricia J Miyake
Tobin C Schilke
Ahmad Y Sheikh
Gopichand Yalamanchili
Partha S Mudipalli
Christine B Seymour
Jodi L Moe
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0212822A publication Critical patent/BR0212822A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"FORMAS CRISTALINAS DE N-(2-HIDROXIACETIL)5-(4-PIPERIDIL)-4-(4-PIRIMIDINIL)-3-(4-CLO ROFENIL)PIRAZOL E COMPOSIçõES FARMACêUTICAS CONTENDO AS MESMAS". A presente invenção refere-se a formas cristalinas do inibidor de p38 quinase N-(2-hidroxiacetil)-5-(4-piperidil)-4-(4-pirimidinil)-3-(4-clorofenil) pirazol. Estas formas cristalinas incluem: (a) uma primeira forma cristalina anidra possuindo estabilidade física melhorada com relação a outras formas de estado sólido do Composto; (b) uma segunda forma cristalina anidra possuindo propriedades únicas com relação a outras formas de estado sólido do Composto; (c) uma terceira forma cristalina anidra possuindo propriedades únicas com relação a outras formas de estado sólido do Composto; e (d) formas cristalinas solvatadas, formas cristalinas hidratadas, e formas cristalinas salinas do Composto que são úteis, por exemplo, como formas de estado sólido intermediárias na preparação de outras formas cristalinas do Composto. São também fornecidas combinações e composições farmacêuticas compreendendo pelo menos uma destas formas cristalinas, processos para o preparo destas formas cristalinas e para preparo das composições compreendendo estas formas cristalinas, e métodos para profilaxia e/ou tratamento de uma condição mediada por p38 quinase compreendendo a administração a um paciente de um montante terapeuticamente eficaz de pelo menos uma destas formas cristalinas.
BR0212822-5A 2001-09-25 2002-09-25 Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas BR0212822A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32498701P 2001-09-25 2001-09-25
PCT/US2002/030538 WO2003026662A1 (en) 2001-09-25 2002-09-25 Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole

Publications (1)

Publication Number Publication Date
BR0212822A true BR0212822A (pt) 2005-08-30

Family

ID=23265959

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212822-5A BR0212822A (pt) 2001-09-25 2002-09-25 Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas

Country Status (8)

Country Link
US (1) US6872725B2 (pt)
EP (1) EP1429772A1 (pt)
JP (1) JP2005529060A (pt)
BR (1) BR0212822A (pt)
CA (1) CA2461080A1 (pt)
MX (1) MXPA04002762A (pt)
WO (1) WO2003026662A1 (pt)
ZA (1) ZA200402323B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
PE20100742A1 (es) * 2005-11-15 2010-11-25 Glaxo Group Ltd Nuevos procedimientos y formulaciones
RS53150B (en) * 2008-11-14 2014-06-30 E. I. Du Pont De Nemours And Company PROCEDURE FOR PREPARING A NON-HYDRATABLE CRYSTAL FORM

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
CA2118517C (en) 1992-06-10 2003-10-14 Gary G. Liversidge Surface modified nsaid nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors

Also Published As

Publication number Publication date
CA2461080A1 (en) 2003-04-03
WO2003026662A1 (en) 2003-04-03
MXPA04002762A (es) 2004-06-29
ZA200402323B (en) 2005-04-29
US6872725B2 (en) 2005-03-29
EP1429772A1 (en) 2004-06-23
JP2005529060A (ja) 2005-09-29
US20030153583A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE457171T1 (de) Kombinationstherapie substituierter oxazolidinone
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
WO2004078746A3 (en) 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
WO2003048164A3 (en) Adenosine a2a receptor antagonists
BRPI0111591B8 (pt) composto, composição farmacêutica, e, usos de um composto
GB0102672D0 (en) Compounds
SE0202429D0 (sv) Novel Compounds
WO2003051277A3 (en) Novel compounds
ES2186550A1 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
SE9803518D0 (sv) Novel compounds
SE9701304D0 (sv) Compounds
SE9803773D0 (sv) Compounds
BR0212822A (pt) Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas
SE0002729D0 (sv) Novel compound form
MXPA04004443A (es) Derivados de pirazol.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
EE200100188A (et) Optiliselt aktiivne püridüül-4H-1,2,4-oksadiasiini derivaat ja selle kasutamine vaskulaarsete haiguste ravis
RU2008143704A (ru) КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ А) ПИРИМИДИЛАМИНОБЕНЗАМИД И Б) ИНГИБИТОР КИНАЗЫ Thr315lle
SE0102641D0 (sv) Novel compounds
ATE265423T1 (de) Neue phenylheteroalkylamin-derivate
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.